Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 14/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103915 | 1.00 | UGCG (0.66) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL3103924 | 1.00 | UGCG (0.66) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL1088041 | 0.90 | UGCG (0.69) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL14068805 | 0.84 | UGCG (0.58) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL2168823 | 0.84 | UGCG (0.64) | UGCGSMN1; SMN2KDM4EPOLB | |
| SCHEMBL7928972 | 0.84 | UGCG (0.64) | UGCGSMN1; SMN2KDM4EPOLB | |
| SCHEMBL17635995 | 0.84 | UGCG (0.61) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL7925240 | 0.84 | UGCG (0.61) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL2167498 | 0.83 | UGCG (0.60) | UGCGSMN1; SMN2KDM4EPOLB | |
| SCHEMBL2167501 | 0.83 | UGCG (0.60) | UGCGSMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209473-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | Genzyme Corporation (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2167485-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009045503-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |